Oophorectomy as a Hormonal Ablation Therapy in Metastatic and Recurrent Breast Cancer: Current Indications and Results

Metwally, Islam H.; Hamdy, Omar; Elbalka, Saleh S.; Elbadrawy, Mohamed; Elsaid, Dina M

doi:10.1007/s13193-019-00938-1

Cited by 6 publications

(7 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This can be accomplished either by preventing the ovaries from making hormones or by interfering with the function of estrogen and progesterone. Pre-menopausal patients who still produce estrogen in the ovaries have traditionally been treated by surgically removing the ovaries though endocrine therapy has decreased this practice in recent years [511][512][513][514]. Resistant mutations arising from endocrine therapy treatment have been thoroughly reviewed recently [515,516].…”

Section: Classificationmentioning

confidence: 99%

Secondary Resistant Mutations to Small Molecule Inhibitors in Cancer Cells

Hamid

Petreaca

2020

Cancers

View full text Add to dashboard Cite

Secondary resistant mutations in cancer cells arise in response to certain small molecule inhibitors. These mutations inevitably cause recurrence and often progression to a more aggressive form. Resistant mutations may manifest in various forms. For example, some mutations decrease or abrogate the affinity of the drug for the protein. Others restore the function of the enzyme even in the presence of the inhibitor. In some cases, resistance is acquired through activation of a parallel pathway which bypasses the function of the drug targeted pathway. The Catalogue of Somatic Mutations in Cancer (COSMIC) produced a compendium of resistant mutations to small molecule inhibitors reported in the literature. Here, we build on these data and provide a comprehensive review of resistant mutations in cancers. We also discuss mechanistic parallels of resistance.

show abstract

Section: Classificationmentioning

confidence: 99%

Secondary Resistant Mutations to Small Molecule Inhibitors in Cancer Cells

Hamid

Petreaca

2020

Cancers

View full text Add to dashboard Cite

show abstract

“…Hormone receptor (HR)-positive breast cancer has a better prognosis and is treated using adjuvant and endocrine therapy, including surgical ablation [ 5 ]. In the last few decades, ovarian function suppression (OFS), a type of extended adjuvant endocrine therapy, has been administered to premenopausal breast cancer patients.…”

Section: Introductionmentioning

confidence: 99%

Comparison of outcomes in patients with luminal type breast cancer treated with a gonadotropin-releasing hormone analog or bilateral salpingo-oophorectomy: A cohort retrospective study

Andriyanto

Prihantono

Syamsu

et al. 2022

Annals of Medicine &Amp; Surgery

View full text Add to dashboard Cite

“…OFS, which can eliminate or reduce ovarian estrogen production, was the first endocrine therapy to be investigated for use in premenopausal breast cancer patients. Initially, OFS was achieved through surgical bilateral oophorectomy or ovarian irradiation [ 24 , 27 ]. However, more recently, GnRHa (also known as luteinizing hormone-releasing hormone agonists) has been used to achieve this outcome [ 33 , 37 ].…”

Section: Introductionmentioning

confidence: 99%

Major depressive symptoms in breast cancer patients with ovarian function suppression: a cross-sectional study comparing ovarian ablation and gonadotropin-releasing hormone agonists

Jiang

Cai

et al. 2021

BMC Psychiatry

View full text Add to dashboard Cite

Background Ovarian function suppression (OFS) is indicated in premenopausal women with early or metastasis breast cancer, which may be achieved with similar effect by gonadotropin-releasing hormone agonists (GnRHa) or ovarian ablation (OA). We examined whether there were differences in major depressive symptoms outcomes and its associated factors between gonadotropin-releasing hormone agonists (GnRHa) and ovarian ablation (OA) in premenopausal breast cancer patients. Methods Premenopausal breast cancer patients from seven hospitals who received OFS participated in the study between June 2019 and June 2020. The correlated variable was the type of ovarian suppression, categorized as either OA (n = 174) or GnRHa (n = 389). Major depressive symptoms was evaluated using the Patient Health Questionnaire (PHQ-9), and the Female Sexual Function Index questionnaire was used to assess sexual function. Results A total of 563 patients completed the surveys. The mean PHQ-9 sum score was slightly lower in the GnRHa cohort than in the OA cohort (11.4 ± 5.7 vs. 12.8 ± 5.8, P = 0.079). There were significantly fewer patients with major depressive symptoms (PHQ-9 ≥ 15) in the GnRHa cohort (31.1% vs. 40.2%, Exp (B)=1.805, P=0.004). Further, breast-conserving surgery and sexual dysfunction were negatively correlated with major depressive symptoms [mastectomy vs. breast-conserving: Exp (B) = 0.461, P <0.001;[sexual dysfunction vs. normal: Exp (B) = 0.512, P = 0.001]. Conclusions This is the first study to demonstrate that GnRHa results in more favorable depressive symptoms outcomes than OA. Moreover, most patients preferred alternatives to their OFS treatment. These findings can contribute to improving and alleviating the adverse effects of OFS.

show abstract

Oophorectomy as a Hormonal Ablation Therapy in Metastatic and Recurrent Breast Cancer: Current Indications and Results

Cited by 6 publications

References 12 publications

Secondary Resistant Mutations to Small Molecule Inhibitors in Cancer Cells

Secondary Resistant Mutations to Small Molecule Inhibitors in Cancer Cells

Comparison of outcomes in patients with luminal type breast cancer treated with a gonadotropin-releasing hormone analog or bilateral salpingo-oophorectomy: A cohort retrospective study

Major depressive symptoms in breast cancer patients with ovarian function suppression: a cross-sectional study comparing ovarian ablation and gonadotropin-releasing hormone agonists

Contact Info

Product

Resources

About